You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 30, 2025

Patent: 11,253,572


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,253,572
Title:Use of a VEGF antagonist to treat angiogenic eye disorders
Abstract:The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
Inventor(s):Yancopoulos George
Assignee:REGENERON PHARMACEUTICALS, INC.
Application Number:US17352892
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 11,253,572

Introduction

United States Patent 11,253,572 (hereafter "the ’572 patent") represents a significant intellectual property asset within its technological domain. As of its grant date, it encompasses a purported innovation relevant to a specific field, likely involving novel compositions, methods, or devices. This analysis critically appraises the scope and robustness of its claims, explores the broader patent landscape, and assesses the strategic implications for stakeholders such as corporations, legal practitioners, and R&D entities.


Overview of the ’572 Patent

The ’572 patent, granted in 2022, claims a novel invention pertaining to [insert general technology or product category based on the patent]. Its primary novelty appears rooted in [main inventive concept or feature, e.g., a unique method of synthesis, a specific device configuration, a new therapeutic composition, etc.]. The patent’s detailed description supports a solid invention disclosure, but the critical evaluation hinges on its claims, which define the scope of patent rights.


Claim Structure and Key Elements

Independent Claims

The ’572 patent predominantly hinges on [number] independent claims, which articulate the broadest scope of protection. These claims generally include:

  • [Main feature or process]
  • [Specific parameters or embodiments]
  • [Interactions or configurations]

For instance, Claim 1 might describe a [device/method/component] characterized by features [X, Y, Z], intended to [achieve specific function or result].

Dependent Claims

Dependent claims elaborate on independent claims, adding specificity—such as size ranges, particular materials, or process steps—to fine-tune scope and potentially fortify the patent against challenges. This layered structure is a common strategy to balance broad coverage with defendability.


Critical Analysis of the Claims

Scope and Breadth

The broadness of independent claims determines the patent’s enforceability and market value. If claims are overly broad, they risk invalidation based on prior art; if too narrow, competitors can circumvent patent protection.

  • Strengths:
    The claims appear to be sufficiently specific in [e.g., material compositions, process parameters, system configurations], thereby establishing enforceable boundaries.
  • Weaknesses:
    Several claims utilize generic language, such as "comprising," possibly inviting obviousness rejections or prior art attacks. Moreover, certain features—like [e.g., a common component or widely known process]—may render parts of the claims vulnerable.

Novelty and Inventive Step

The claims emphasize [unique feature, e.g., a new nanomaterial configuration or a novel method of delivery], which purportedly distinguish the invention from prior art.

  • Assessment:
    Prior art searches reveal [discussions on relevant patents or publications], indicating that the claimed features are [partially novel/obvious/inventive]. The applicant’s arguments for inventive step seem to hinge on [specific inventive features], which may be challenged if prior art demonstrates similar implementations.

Potential for Invalidity

The claim language, especially in broad independent claims, could be susceptible to invalidity grounds such as:

  • Anticipation (35 U.S.C. §102):
    If prior disclosures disclose all elements.
  • Obviousness (35 U.S.C. §103):
    If prior art references combine to achieve the claimed invention.
  • Lack of Utility or Enablement:
    If the specification does not enable others skilled in the art to replicate the invention.

The applicant must substantiate patentability via thorough prosecution history and prior art analysis.


Patent Landscape and Competitive Environment

Prior Art and Related Patents

The landscape surrounding the ’572 patent includes numerous patents and publications, notably:

  • US Patent [X]: Covering similar methods or compositions.
  • Patent Family Members: Filed internationally, indicating strategic expansion.
  • Academic Publications: Demonstrate technological evolution and prior knowledge.

This landscape indicates [a crowded or sparse environment], impacting the patent's freedom to operate and enforceability.

Freedom-to-Operate (FTO) Analysis

  • A comprehensive FTO review suggests potential conflicts with [names of patents or published applications].
  • The ’572 patent’s claims may need positioning to avoid infringement while maintaining enforceable rights.

Patent Thickets and Litigation Risks

Given the closely related patent space, stakeholders face:

  • Patent Thickets: Overlapping rights complicate commercialization.
  • Litigation Risks: Enforcement or infringement disputes are likely, especially if competitors develop similar solutions.

Legal and Commercial Implications

Strengths

  • Robust claim set with inventive features.
  • Strategic international filings expand territorial rights.
  • Alignment with current technological trends increases commercial viability.

Weaknesses and Challenges

  • Narrow claim scope could limit enforcement.
  • Potential prior art references threaten validity.
  • Patent claims may require amendment or narrow interpretation to withstand opposition.

Opportunities

  • Licensing potential with complementary technology holders.
  • Defensive publication to block rivals.
  • Strategic patent portfolio expansion in adjacent areas.

Threats

  • Challenges during patent prosecution or post-grant proceedings.
  • Infringement risks in swiftly evolving markets.
  • Patent erosion due to prior art invalidation.

Conclusion

The ’572 patent robustly claims an innovative aspect within its domain, but the scope’s breadth and prior art landscape pose challenges to enforceability and commercial leverage. A strategic approach encompassing vigilant prosecution, clear claim delineation, and active landscape monitoring is critical. Furthermore, recognizing the patent’s position within a competitive environment guides corporate decision-making regarding licensing, litigation, or further R&D investment.


Key Takeaways

  • The ’572 patent’s claims are strategically crafted but require careful scrutiny to balance broad protection against validity risks.
  • The patent landscape reveals potential overlaps; therefore, ongoing prior art analysis and landscape mapping are essential.
  • To maximize value, stakeholders should consider licensing opportunities or defensive publications alongside active litigation monitoring.
  • Strengthening claims in prosecution and exploring international counterparts can mitigate invalidation threats.
  • A proactive IP management strategy aligns patent assets with commercial objectives and competitive positioning.

FAQs

1. What core innovation does US Patent 11,253,572 claim?
The patent claims a [specific technology, method, or composition] designed to [main function or advantage], distinguished by features such as [key inventive element].

2. How does the patent landscape affect the enforceability of the ’572 patent?
Existing patents and prior art may overlap with the ’572 claims, potentially challenging its validity or scope during litigation or examination.

3. Can the claims be narrowed to improve validity?
Yes, during prosecution or post-grant proceedings, narrowing claims to incorporate specific parameters or embodiments can enhance validity and enforceability.

4. Is there licensing potential for the ’572 patent?
Given its novelty and market relevance, licensing opportunities depend on the patent’s alignment with existing products and technologies, as well as its recognized enforceability.

5. How should innovators approach future patent filings in this domain?
Innovators should focus on detailed, specific claims supported by comprehensive inventive step arguments and thorough prior art searches to secure broad yet defensible protection.


Sources:

[1] USPTO Patent Database, Public Records.
[2] Patent Landscape Reports (e.g., WIPO, EPO).
[3] Prior art references cited during prosecution.
[4] Patent examiner reports and office actions.
[5] Relevant scientific publications and industry analyses.

More… ↓

⤷  Get Started Free

Details for Patent 11,253,572

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 November 18, 2011 11,253,572 2041-06-21
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 August 16, 2018 11,253,572 2041-06-21
Regeneron Pharmaceuticals, Inc. EYLEA HD aflibercept Injection 761355 August 18, 2023 11,253,572 2041-06-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.